ArticleAnnals of medicine2026
Drug repurposing of ticagrelor suppresses renal cell carcinoma growth by blockading the EGFR/PI3K/AKT axis.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRenal cell carcinoma (RCC) remains one of the most prevalent urological malignancies. Although targeted therapies have expanded therapeutic options, a substantial proportion of patients still experience poor outcomes, underscoring the need for more effective and less toxic strategies. Ticagrelor, a novel antiplatelet agent, has recently shown antineoplastic potential in several cancers; however, its role and mechanism in RCC remain undefined.
methodsIn vitro effects of ticagrelor on RCC cells were evaluated using CCK-8, EdU, and AO/PI assays for proliferation/apoptosis, wound healing and Transwell assays for migration/invasion.
resultsTicagrelor suppressed proliferation, migration, invasion and adhesion, and promoted apoptosis in RCC cells. In CDX mice, tumor growth was significantly inhibited. Mechanistically, the EGFR/PI3K/AKT pathway was identified as the key mediator of ticagrelor's antitumor activity in RCC.
conclusionsTicagrelor exerts anti-RCC effects
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.